仑伐替尼联合帕博利珠单抗治疗晚期胃癌的开放标签单臂2期试验
EPOC1706是一项开放标签、单臂2期试验,纳入29例晚期胃或胃食管结合部腺癌患者,接受仑伐替尼20mg每日口服联合帕博利珠单抗200mg每3周静脉注射。客观缓解率达69%(95%CI 49-85),常见3级治疗相关不良事件为高血压(38%)、蛋白尿(17%)和血小板计数下降(7%),无4级不良事件或治疗相关死亡。
要点
- 仑伐替尼联合帕博利珠单抗在晚期胃癌中显示较高客观缓解率(69%)。
- 安全性可接受,常见3级不良事件为高血压、蛋白尿和血小板减少。
- 结果支持未来开展确证性试验。
核心结论
- 仑伐替尼联合帕博利珠单抗在晚期胃癌患者中显示出有前景的抗肿瘤活性和可接受的安全性。
研究设计与样本
- 开放标签、单臂2期试验,在日本国家癌症中心东医院开展,纳入29例晚期胃或胃食管结合部腺癌患者。
- 患者接受仑伐替尼20mg每日口服联合帕博利珠单抗200mg每3周静脉注射,直至疾病进展、不可耐受毒性或撤回知情同意。
主要发现
- 29例患者中20例(69%,95%CI 49-85)达到客观缓解。
- 常见3级治疗相关不良事件为高血压(11例[38%])、蛋白尿(5例[17%])和血小板计数下降(2例[7%])。
- 未发生4级治疗相关不良事件、严重治疗相关不良事件或治疗相关死亡。
关键数值与推荐
- 主要终点为符合RECIST的客观缓解率,在全部合格且至少接受一次方案治疗的患者中分析。
- 安全性分析纳入所有至少接受一次方案治疗的患者,无论是否符合入选标准。
临床怎么用
- 该联合方案可作为晚期胃癌一线或二线治疗的潜在选择,但需等待确证性试验结果。
- 治疗期间应重点监测高血压、蛋白尿和血小板计数。
局限性
- 单臂设计、样本量小(29例),无对照组,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab, an anti-PD-1 antibody, results in tumour response in around 15% of patients with advanced gastric cancer who have a PD-L1 combined positive score of at least 1. Lenvatinib, a multikinase inhibitor of VEGF receptors and other receptor tyrosine kinases, substantially decreased tumour-associated macrophages and increased infiltration of CD8 T cells, resulting in enhanced anti-tumour activity of PD-1 inhibitors in an in-vivo model. We aimed to assess the combination of lenvatinib plus pembrolizumab in patients with advanced gastric cancer in a phase 2 study. METHODS: This study was an open-label, single-arm, phase 2 trial undertaken at the National Cancer Center Hospital East (Chiba, Japan). Eligible patients were aged 20 years or older and had metastatic or recurrent adenocarcinoma of the stomach or gastro-oesophageal junction, an Eastern Cooperative Oncology Group performance status of 0 or 1, and measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), irrespective of the number of previous lines of treatment. Patients received 20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks until disease progression, development of intolerable toxicity, or withdrawal of consent. The primary endpoint was objective response rate according to RECIST, analysed in all patients who were eligible and received protocol treatment at least once. The safety analysis included all those who received protocol treatment at least once, regardless of eligibility. This study is registered at ClinicalTrials.gov, NCT03609359, and enrolment is complete. FINDINGS: Between Oct 15, 2018, and March 25, 2019, 29 patients were enrolled in the first-line or second-line settings. At data cutoff (March 20, 2020), the median follow-up was 12·6 months (IQR 10·5-14·3). 20 (69%, 95% CI 49-85) of 29 patients had an objective response. The most common grade 3 treatment-related adverse events were hypertension (in 11 [38%] patients), proteinuria (five [17%]), and platelet count decrease (two [7%]). No grade 4 treatment-related adverse events, serious treatment-related adverse events, or treatment-related deaths occurred. INTERPRETATION: Lenvatinib plus pembrolizumab showed promising anti-tumour activity with an acceptable safety profile in patients with advanced gastric cancer. On the basis of these results, a confirmatory trial will be planned in the future. FUNDING: Merck Sharp & Dohme.
引用
- Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020. PMID: 32589866. doi:10.1016/S1470-2045(20)30271-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。